# VTRS PDUFA Calendar: FDA Decision Dates & Catalyst Timeline

Canonical URL: https://biopharmsignal.com/pdufa-calendar/VTRS
Company: Viatris Inc.

BioPharmSignal tracks active PDUFA and FDA decision milestones associated with VTRS.

## VTRS PDUFA Milestones

- 2026-10-17 — PDUFA — FDA decision expected. FDA assigned an October 17, 2026 PDUFA goal date to the MR-141 supplemental NDA seeking a presbyopia indication for phentolamine ophth...
  Company: Viatris Inc.
  Source: https://newsroom.viatris.com/2026-02-25-FDA-Accepts-Viatris-Supplemental-New-Drug-Application-for-MR-141-Phentolamine-Ophthalmic-Solution-0-75-for-the-Treatment-of-Presbyopia
  Event detail: https://biopharmsignal.com/pdufa-calendar/VTRS/mr-141-presbyopia.md
  Month page: https://biopharmsignal.com/pdufa-calendar/2026/october (October 2026)

## Related Pages

- Company page: https://biopharmsignal.com/company/VTRS
- Interactive PDUFA Calendar: https://biopharmsignal.com/pdufa-calendar

## FAQ

### What does the VTRS PDUFA calendar show?

It shows active PDUFA and FDA decision milestones associated with VTRS, including decision dates, application stage, and summary details when available.
### Where can I find more context for VTRS?

Use the BioPharmSignal company page for VTRS to read related news, stock data, sector context, and company-specific updates.
### Are these dates investment advice?

No. PDUFA dates are research inputs, not investment recommendations. Always review primary sources and understand the clinical and regulatory context.